Possibilities for optimization of eradication therapy for Helicobacter pylori infection in modern clinical practice
- Authors: Andreev DN1, Dicheva DT1, Maev IV1
-
Affiliations:
- Московский государственный медико-стоматологический университет им. А.И. Евдокимова Минздрава России
- Issue: Vol 89, No 2 (2017)
- Pages: 84-90
- Section: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/32220
- DOI: https://doi.org/10.17116/terarkh201789284-90
- ID: 32220
Cite item
Full Text
Abstract
A steady decline in the effectiveness of standard eradication therapy (ET) regimens for Helicobacter pylori infection necessitates a search for ways of their optimization, by enhancing the efficiency of treatment protocols and by improving their safety and tolerability. The review systematizes the data available in the literature on main accessible methods for optimizing ET regimens. Among the optimization methods that can considerably enhance the efficiency of ET regimens, one may identify their addition of a bismuth agent (by 10—20%), the use of rebamipide (by 11.9%), adjuvant therapy with probiotics (by 8.1—13%), or double-dose proton pump inhibitors (by 8%). Only adjuvant therapy with probiotics results in a significant decrease in the incidence of side effects from ET. In posteradication period, rebamipide should be used to potentiate gastric mucosal repair and to regress inflammatory processes.
Full Text
##article.viewOnOriginalSite##About the authors
D N Andreev
Московский государственный медико-стоматологический университет им. А.И. Евдокимова Минздрава РоссииМосква, Россия
D T Dicheva
Московский государственный медико-стоматологический университет им. А.И. Евдокимова Минздрава РоссииМосква, Россия
I V Maev
Московский государственный медико-стоматологический университет им. А.И. Евдокимова Минздрава РоссииМосква, Россия
References
- Маев И.В., Самсонов А.А., Андреев Д.Н. Инфекция Helicobacter pylori. М.: ГЭОТАР-Медиа; 2016.
- Маев И.В., Самсонов А.А., Андреев Д.Н., Гречушников В.Б., Коровина Т.И. Клиническое значение инфекции Helicobacter pylori. Клиническаямедицина. 2013;91(8):4-12.
- Sugano K, Tack J, Kuipers EJ, Graham DY, El-Omar EM, Miura S, Haruma K, Asaka M, Uemura N, Malfertheiner P; faculty members of Kyoto Global Consensus Conference. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015; 64(9):1353-1367. doi: 10.1136/gutjnl-2015-309252
- Malfertheiner P, Link A, Selgrad M. Helicobacter pylori: perspectives and time trends. Nat Rev Gastroenterol Hepatol. 2014; 11(10):628-638. doi: 10.1038/nrgastro.2014.99
- Peek RM Jr, Crabtree JE. Helicobacter infection and gastric neoplasia. J Pathol. 2006;208(2):233-248. doi: 10.1002/path.1868
- Kusters JG, van Vliet AH, Kuipers EJ. Pathogenesis of Helicobacter pylori infection. Clin Microbiol Rev. 2006;19(3):449-490. doi: 10.1128/CMR.00054-05
- Маев И.В., Андреев Д.Н., Самсонов А.А., Дичева Д.Т., Парцваниа-Виноградова Е.В. Эволюция представлений о дефиниции, классификации, диагностике и лечении гастрита, ассоциированного с инфекцией Helicobacter pylori (по материалам Киотского консенсуса, 2015). Фарматека. 2016;6:24-33.
- Malfertheiner P, Megraud F, O’Morain CA, Gisbert JP, Kuipers EJ, Axon AT, Bazzoli F, Gasbarrini A, Atherton J, Graham DY, Hunt R, Moayyedi P, Rokkas T, Rugge M, Selgrad M, Suerbaum S, Sugano K, El-Omar EM. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2016. pii: gutjnl-2016-312288. doi: 10.1136/gutjnl-2016-312288
- Graham DY, Dore MP. Helicobacter pylori therapy: a paradigm shift. Expert Rev Anti Infect Ther. 2016;14(6):577-585. doi: 10.1080/14787210.2016.1178065
- Safavi M, Sabourian R, Foroumadi A. Treatment of Helicobacter pylori infection: Current and future insights. World J Clin Cases. 2016;4(1):5-19. doi: 10.12998/wjcc.v4.i1.5
- Malfertheiner P, Megraud F, O’Morain C, Bazzoli F, El-Omar E, Graham D, Hunt R, Rokkas T, Vakil N, Kuipers EJ. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut. 2007;56:772-781. doi: 10.1136/gut.2006.101634
- Маев И.В., Кучерявый Ю.А., Андреев Д.Н., Баркалова Е.В. Эрадикационная терапия инфекции Helicobacter pylori: обзор мировых тенденций. Тер. архив. 2014;3:94-99.
- Maev IV, Andreev DN, Kucheryavyi YuA, Dicheva DT. Host factors influencing the eradication rate of Helicobacter pylori. World Applied Sci J. 2014;30:134-140. doi: 10.5829/idosi.wasj.2014.30.mett.61
- Uotani T, Miftahussurur M, Yamaoka Y. Effect of bacterial and host factors on Helicobacter pylori eradication therapy. Expert Opin Ther Targets. 2015;19(12):1637-1650. doi: 10.1517/14728222.2015.1073261
- Маев И.В., Кучерявый Ю.А., Андреев Д.Н. Актуальные возможности оптимизации антихеликобактерной терапии. Лечащийврач. 2014;4:73-79.
- Sabaté E, ed. Adherence to Long-Term Therapies: Evidence for Action. Geneva, Switzerland: World Health Organization; 2003.
- O’Connor JP, Taneike I, O’Morain C. Improving compliance with Helicobacter pylori eradication therapy: when and how? Therap Adv Gastroenterol. 2009;2(5):273-279. doi: 10.1177/1756283X09337342
- Wermeille J, Cunningham M, Dederding JP, Girard L, Baumann R, Zelger G, Buri P, Metry JM, Sitavanc R, Gallaz L, Merki H, Godin N.Failure of Helicobacter pylori eradication: is poor compliance the main cause? Gastroenterol Clin Biol. 2002;26(3):216-219.
- Tschabitscher D, Platzer P, Baumgärtel C, Müllner M. Generic drugs: quality, efficacy, safety and interchangeability. WienKlinWochenschr. 2008;120(3-4):63-69. doi: 10.1007/s00508-008-0927-3
- Передерий В.Г., Чернявский В.В. Медико-экономическая эффективность стандартных схем эрадикации H. pylori с включением оригинального и генерического рабепразола. Здоров’яУкраїни. 2006;21/1:28-29.
- Cammarota S, Bruzzese D, Sarnelli G, Citarella A, Menditto E, Riegler S, Savino IG, Vozzella L, Piccinocchi G, Napoli L, Arpino G, Cuomo R. Proton pump inhibitors prescribing following the introduction of generic drugs. Eur J Clin Invest. 2012;42(10):1068-1078. doi: 10.1111/j.1365-2362.2012.02696.x
- Tepes B, O’Connor A, Gisbert J, O’Morain C. Treatment of Helicobacter pylori infection 2012. Helicobacter. 2012;17(Suppl.1):36-42. doi: 10.1111/j.1523-5378.2012.00981.x
- Vallve M, Vergara M, Gisbert J P, Calvet X. Single vs. double dose of a proton pump inhibitor in triple therapy for Helicobacter pylori eradication: a meta-analysis. Aliment Pharmacol Ther. 2002; 16(6):1149-1156. doi: 10.1046/j.1365-2036.2002.01270.x
- Villoria A, Garcia P, Calvet X, Gisbert JP, Vergara M. Meta-analysis: high-dose proton pump inhibitors vs. standard dose in triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther. 2008;28(7):868-877. doi: 10.1111/j.1365-2036.2008.03807.x
- McNicholl AG, Linares PM, Nyssen OP, Calvet X, Gisbert JP. Meta-analysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther. 2012;36(5):414-425. doi: 10.1111/j.1365-2036.2012.05211.x
- Chaudhry AS, Kochhar R, Kohli KK. Genetic polymorphism of CYP2C19 & therapeutic response to proton pump inhibitors. Indian J Med Res. 2008;127(6):521-530.
- Kuo CH, Lu CY, Shih HY, Liu CJ, Wu MC, Hu HM, Hsu WH, Yu FJ, Wu DC, Kuo FC. CYP2C19 polymorphism influences Helicobacter pylori eradication. World J Gastroenterol. 2014;20 (43):16029-16036. doi: 10.3748/wjg.v20.i43.16029
- Zvyaga T, Chang SY, Chen C, Yang Z, Vuppugalla R, Hurley J, Thorndike D, Wagner A, Chimalakonda A, Rodrigues AD. Evaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450: focus on cytochrome P450 2C19. Drug Metab Dispos. 2012;40(9):1698-1711. doi: 10.1124/dmd.112.045575
- Skoczylas T, Sarosiek I, Sostarich S, McElhinney C, Durham S, Sarosiek J. Significant enhancement of gastric mucin content after rabeprazole administration: its potential clinical significance in acid-related disorders. Dig Dis Sci. 2003;48(2):322-328.
- Jaworski T, Sarosiek I, Sostarich S, Roeser K, Connor M, Brotze S, Wallner G, Sarosiek J. Restorative impact of rabeprazole on gastric mucus and mucin production impairment during naproxen administration: its potential clinical significance. Dig Dis Sci. 2005;50(2):357-365.
- Tsutsui N, Taneike I, Ohara T, Goshi S, Kojio S, Iwakura N, Matsumaru H, Wakisaka-Saito N, Zhang HM, Yamamoto T. A novel action of the proton pump inhibitor rabeprazole and its thioether derivative against the motility of Helicobacter pylori. Antimicrob Agents Chemother. 2000;44(11):3069-3073.
- Ohara T, Goshi S, Taneike I, Tamura Y, Zhang HM, Yamamoto T. Inhibitory action of a novel proton pump inhibitor, rabeprazole, and its thioether derivative against the growth and motility of clarithromycin-resistant Helicobacter pylori. Helicobacter. 2001;6(2):125-129.
- Zhang Z, Liu ZQ, Zheng PY, Tang FA, Yang PC. Influence of efflux pump inhibitors on the multidrug resistance of Helicobacter pylori. WorldJGastroenterol. 2010;16(10):1279-1284.
- Кучерявый Ю.А., Андреев Д.Н. Перспективы лечения больных с кислотозависимыми заболеваниями. Клин. перспективы гастроэнтерол., гепатол. 2014;2:15-24.
- Akazawa Y, Fukuda D, Fukuda Y. Vonoprazan-based therapy for Helicobacter pylori eradication: experience and clinical evidence. Therap Adv Gastroenterol. 2016;9(6):845-852. doi: 10.1177/1756283X16668093
- Murakami K, Sakurai Y, Shiino M, Funao N, Nishimura A, Asaka M. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study. Gut. 2016;65(9):1439-1446. doi: 10.1136/gutjnl-2015-311304
- Suzuki S, Gotoda T, Kusano C, Iwatsuka K, Moriyama M. The Efficacy and Tolerability of a Triple Therapy Containing a Potassium-Competitive Acid Blocker Compared With a 7-Day PPI-Based Low-Dose Clarithromycin Triple Therapy. Am J Gastroenterol. 2016;111(7):949-956. doi: 10.1038/ajg.2016.182
- Ge R, Chen Z, Zhou Q. The actions of bismuth in the treatment of Helicobacter pylori infections: an update. Metallomics. 2012;4(3):239-243. doi: 10.1039/c2mt00180b
- Alkim H, Koksal AR, Boga S, Sen I, Alkim C. Role of Bismuth in the Eradication of Helicobacter pylori. Am J Ther. 2016 Jan 21.
- Bland MV, Ismail S, Heinemann JA, Keenan JI. The action of bismuth against Helicobacter pylori mimics but is not caused by intracellular iron deprivation. Antimicrob Agents Chemother. 2004;48(6):1983-1988. doi: 10.1128/AAC.48.6.1983-1988.2004
- Stratton CW, Warner RR, Coudron PE, Lilly NA. Bismuth-mediated disruption of the glycocalyx-cell wall of Helicobacter pylori: ultrastructural evidence for a mechanism of action for bismuth salts. J Antimicrob Chemother. 1999;43(5):659-666.
- Кучерявый Ю.А., Андреев Д.Н., Баркалова Е.В. Клинико-молекулярные аспекты резистентности Helicobacter pylori к антибактериальным препаратам. Мед. совет. 2013;10:11-15.
- Williamson R, Pipkin GA. Does bismuth prevent antimicrobial resistance of Helicobacter pylori? Helicobacter pylori. Basic Mechanisms to Clinical Cure 1998. Ed. by RH Hunt, GNJ Tytgat. Dordrecht; Boston; London: Kluwer Acad. Publ., 1998:416-425.
- Sun Q, Liang X, Zheng Q, Liu W, Xiao S, Gu W, Lu H. High efficacy of 14-ay triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication. Helicobacter. 2010;15(3):233-238. doi: 10.1111/j.1523-5378.2010.00758.x
- Yoon JH, Baik GH, Kim YS, Suk KT, Shin WG, Kim KH, Kim KO, Park CH, Baik IH, Jang HJ, Kim JB, Kae SH, Kim DJ, Kim HY. Comparison of the Eradication Rate between 1-nd 2-Week Bismuth-Containing Quadruple Rescue Therapies for Helicobacter pylori Eradication. Gut Liver. 2012;6(4):434-439. doi: 10.5009/gnl.2012.6.4.434
- Liao J, Zheng Q, Liang X, Zhang W, Sun Q, Liu W, Xiao S, Graham DY, Lu H. Effect of fluoroquinolone resistance on 14-day levofloxacin triple and triple plus bismuth quadruple therapy. Helicobacter 2013;18:373-377. doi: 10.1111/hel.12052
- Cao Z, Chen Q, Zhang W, Liang X, Liao J, Liu W, Xiao S, Lu H. Fourteen-day optimized levofloxacin-based therapy versus classical quadruple therapy for Helicobacter pylori treatment failures: a randomized clinical trial. Scand J Gastroenterol. 2015;50(10): 1185-1190. doi: 10.3109/00365521.2015.1037345
- Dore MP, Lu H, Graham DY. Role of bismuth in improving Helicobacter pylori eradication with triple therapy. Gut. 2016;65(5):870-878. doi: 10.1136/gutjnl-2015-311019
- Маев И.В., Самсонов А.А., Коровина Т.И., Гречушников В.Б., Андреев Н.Г. Висмута трикалия дицитрат повышает эффективность антихеликобактерной терапии первой линии. Эксперимент. и клин. гастроэнтерол. 2012;8:92-97.
- Бордин Д.С., Машарова А.А., Хомерики С.Г. Хронический гастрит: современный взгляд на старую проблему. Эксперимент. иклин. гастроэнтерол. 2012;5:99-106.
- Iinuma S, Naito Y, Yoshikawa T, Takahashi S, Takemura T, Yoshida N, Kondo M. In vitro studies indicating antioxidative properties of rebamipide. Dig Dis Sci. 1998;43(9 Suppl):35S-39S.
- Yoshida N, Yoshikawa T, Iinuma S, Arai M, Takenaka S, Sakamoto K, Miyajima T, Nakamura Y, Yagi N, Naito Y, Mukai F, Kondo M. Rebamipide protects against activation of neutrophils by Helicobacter pylori. Dig Dis Sci. 1996;41(6):1139-1144.
- Naito Y, Yoshikawa T. Rebamipide: a gastrointestinal protective drug with pleiotropic activities. Expert Rev Gastroenterol Hepatol. 2010;4(3):261-270. doi: 10.1586/egh.10.25
- Haruma K, Ito M. Review article: clinical significance of mucosal-protective agents: acid, inflammation, carcinogenesis and rebamipide. Aliment Pharmacol Ther. 2003;18(Suppl.1):153-159. doi: 10.1046/j.1365-2036.18.s1.17.x
- Haruma K, Ito M, Kido S, Manabe N, Kitadai Y, Sumii M, Tanaka S, Yoshihara M, Chayama K. Long-term rebamipide therapy improves Helicobacter pylori-associated chronic gastritis. Dig Dis Sci. 2002;47(4):862-867.
- Kamada T, Sato M, Tokutomi T, Watanabe T, Murao T, Matsumoto H, Manabe N, Ito M, Tanaka S, Inoue K, Shiotani A, Akiyama T, Hata J, Haruma K. Rebamipide improves chronic inflammation in the lesser curvature of the corpus after Helicobacter pylori eradication: a multicenter study. Biomed Res Int. 2015; 2015:865146. doi: 10.1155/2015/865146
- Nishizawa T, Nishizawa Y, Yahagi N, Kanai T, Takahashi M, Suzuki H. Effect of supplementation with rebamipide for Helicobacter pylori eradication therapy: a systematic review and meta-analysis. J Gastroenterol Hepatol. 2014;29(Suppl.4):20-24. doi: 10.1111/jgh.12769
- Terano A, Arakawa T, Sugiyama T, Suzuki H, Joh T, Yoshikawa T, Higuchi K, Haruma K, Murakami K, Kobayashi K; Rebamipide Clinical Study Group. Rebamipide, a gastro-protective and anti-inflammatory drug, promotes gastric ulcer healing following eradication therapy for Helicobacter pylori in a Japanese population: a randomized, double-blind, placebo-controlled trial. J Gastroenterol. 2007;42(8):690-693. doi: 10.1007/s00535-007-2076-2
- Marcus EA, Sachs G, Scott DR. Eradication of Helicobacter pylori Infection. Curr Gastroenterol Rep. 2016;18(7):33. doi: 10.1007/s11894-016-0509-x
- Pinchuk IV, Bressollier P, Verneuil B, Fenet B, Sorokulova IB, Mégraud F, Urdaci MC. In vitro anti-Helicobacter pylori activity of the probiotic strain Bacillus subtilis 3 is due to secretion of antibiotics. Antimicrob Agents Chemother. 2001;45(11):3156-3161. doi: 10.1128/AAC.45.11.3156-3161.2001
- Lesbros-Pantoflickova D., Corthésy-Theulaz I., Blum A. L. Helicobacter pylori and probiotics. J Nutr. 2007;137(3,Suppl.2): 812S-818S.
- Zhou C, Ma FZ, Deng XJ, Yuan H, Ma HS. Lactobacilli inhibit interleukin-8 production induced by Helicobacter pylori lipopolysaccharide-activated Toll-like receptor 4. World J Gastroenterol. 2008;14(32):5090-5095. doi: 10.3748/wjg.14.5090
- Zou J, Dong J, Yu X. Meta-analysis: Lactobacillus containing quadruple therapy versus standard triple first-line therapy for Helicobacter pylori eradication. Helicobacter. 2009;14(5):97-107. doi: 10.1111/j.1523-5378.2009.00716.x
- Szajewska H, Horvath A, Piwowarczyk A. Meta-analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment. Aliment Pharmacol Ther. 2010;32(9):1069-1079. doi: 10.1111/j.1365-2036.2010.04457.x
- Wang ZH, Gao QY, Fang JY. Meta-Analysis of the Efficacy and safety of Lactobacillus-containing and Bifidobacterium-containing probiotic compound preparation in Helicobacter pylori eradication therapy. J Clin Gastroenterol. 2013;47(1):25-32. doi: 10.1097/MCG.0b013e318266f6cf
- Lv Z, Wang B, Zhou X, Wang F, Xie Y, Zheng H, Lv N. Efficacy and safety of probiotics as adjuvant agents for Helicobacter pylori infection: A meta-analysis. Exp Ther Med. 2015;9(3):707-716. doi: 10.3892/etm.2015.2174
- Kamdeu Fansi AA, Guertin JR, LeLorier J. Savings from the use of a probiotic formula in the prophylaxis of antibiotic-associated diarrhea. J Med Econ. 2012;15(1):53-60. doi: 10.3111/13696998.2011.629015
- Самсонов А.А., Гречушников В.Б., Андреев Д.Н., Юренев Г.Л., Лежнева Ю.А., Маев И.В. Оценка фармакоэкономических показателей лечения пациентов с заболеваниями, ассоциированными с Helicobacter pylori. Тер. архив. 2014;86(8):56-61.
- Li G, Li L, Yu C, Chen L. Effect of vitamins C and E supplementation on Helicobacter pylori eradication: a meta-analysis. Br J Nutr. 2011;106(11):1632-1637. doi: 10.1017/S0007114511003813
- Demirci H, Uygun İlikhan S, Öztürk K, Üstündağ Y, Kurt Ö, Bilici M, Köktürk F, Uygun A. Influence of vitamin C and E supplementation on the eradication rates of triple and quadruple eradication regimens for Helicobacter pylori infection. Turk J Gastroenterol. 2015;26(6):456-460. doi: 10.5152/tjg.2015.0233
![](/img/style/loading.gif)